Syneron Medical Ltd.
ELOS, announced today that is has signed a definitive agreement to acquire
Ultrashape Ltd, a leading developer, manufacturer and
marketer of innovative non-invasive technologies for fat cell
destruction and body sculpting. Ultrashape is the sole operating
entity of Ultrashape Medical Ltd. and it owns all rights
and interests in the fat cell reduction and body sculpting business.
Ultrashape's products are approved and commercially available in
Europe, Canada, Latin America and Asia.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in